Praluent 75 mg/ml Pen: What You Should Know

What Is the Praluent 75 mg/ml Pen

Praluent 75 mg/ml pen is a pre-filled, single-dose auto-injector that delivers alirocumab, a monoclonal antibody that targets PCSK9. It is indicated to lower low-density lipoprotein (LDL) cholesterol in adults with hypercholesterolemia or mixed dyslipidemia, often alongside diet and statin therapy. The pen is designed for subcutaneous injection, typically in the thigh or abdomen, and is supplied as a ready-to-use device that removes the need for drawing medication from a vial.

How the Praluent Pen Works

Alirocumab binds to PCSK9, a protein that normally reduces the liver's ability to remove LDL cholesterol from the blood. By blocking PCSK9, the drug increases the number of LDL receptors on liver cells, which clears more LDL from the bloodstream. The 75 mg/ml concentration is one of the strength options; dosing is determined by a healthcare provider based on the patient's lipid levels, response to therapy, and whether they are on a statin. The pen delivers a fixed dose, so the patient does not need to calculate or measure the medication.

Who May Be Prescribed the Praluent Pen

Praluent is generally considered for adults with primary hypercholesterolemia or mixed dyslipidemia who need additional LDL lowering. Common scenarios include patients with atherosclerotic cardiovascular disease who require further risk reduction, individuals with heterozygous familial hypercholesterolemia, or people whose LDL remains above target despite maximally tolerated statin therapy. It is also used in some patients with homozygous familial hypercholesterolemia, though response can vary. Because alirocumab is a biologic, it is not a first-line oral therapy and is typically added when statins alone are insufficient or not tolerated.

Using the Praluent 75 mg/ml Pen

The Praluent pen is intended for once-every-2-weeks dosing, although some patients may be switched to a once-monthly schedule depending on their lipid goals and physician guidance. Before injection, patients should check that the liquid is clear and colorless, confirm the expiration date, and allow the pen to reach room temperature for about 30 minutes. The injection site should be cleaned, and the pen activated according to the device instructions, with the needle inserted and the dose button pressed. Each pen is for single use only and must be disposed of in an approved sharps container. The pre-filled design aims to simplify administration at home, but training from a healthcare professional is recommended before the first use.

Storage and Handling

Praluent 75 mg/ml pens should be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). They may be kept at room temperature up to 25°C (77°F) for a limited period, but once removed from refrigeration, they should not be returned to the fridge. Patients should avoid freezing the pens and protect them from light. Each pen contains a single dose, so any unused medication should be discarded properly. Travelers should keep the pens in a cool bag and follow airline regulations for carrying injectable biologics.

Side Effects and Safety Considerations

Common side effects associated with alirocumab include injection-site reactions such as redness, swelling, or itching, as well as cold-like symptoms, influenza-like illness, and elevated liver enzymes in some cases. Hypersensitivity reactions, including rash and swelling, are possible but less frequent. Patients with a known allergy to alirocumab or any excipients should not use the pen. Because alirocumab lowers LDL cholesterol significantly, doctors may monitor lipid panels and liver function periodically. It is important to discuss any existing liver disease, pregnancy plans, or breastfeeding with a prescriber before starting treatment.

Praluent Pen vs. Other PCSK9 Inhibitors

The main alternatives to alirocumab in the PCSK9 inhibitor class include evolocumab (Repatha), which is also available as a pre-filled injector or autoinjector. Both drug classes work on the same target, but they differ in dosing frequency, device design, and in some patients' tolerability or cost profiles. The choice between them often depends on insurance coverage, formulary preferences, patient preference for device handling, and clinical response. Praluent's 75 mg/ml pen is one strength option; other concentrations exist for different dosing regimens.

Cost, Coverage, and Access

Praluent is a brand-name biologic, and its list price is generally high. Coverage varies widely by insurance plan, with many requiring prior authorization and evidence that statin therapy has been tried or is insufficient. Manufacturers often provide co-pay assistance or savings cards for eligible patients, and some offer patient support programs. Without insurance, the out-of-pocket cost can be substantial, so patients are encouraged to check with their pharmacy and insurer before starting. Biosimilars or alternative PCSK9 inhibitors may offer lower-cost options depending on the market and formulary.

What Patients Should Discuss With Their Doctor

Before starting the Praluent 75 mg/ml pen, patients should review their full lipid profile, cardiovascular risk factors, and current medications. Questions to raise include the expected LDL reduction, injection schedule, how to handle missed doses, what to do if a dose is skipped, and how to store the pen during travel. It is also important to report any side effects promptly and to keep follow-up appointments for lipid monitoring. Because alirocumab is a long-term therapy, adherence to the injection schedule and ongoing communication with the prescribing clinician are key to achieving cardiovascular risk reduction goals.